Endoscopic Cyclophotocoagulation (ECP) in Ophthalmology

Endoscopic cyclophotocoagulation, widely known as ECP, is a laser procedure used to lower eye pressure in people with glaucoma by targeting the ciliary body, the tissue inside the eye that produces fluid. Unlike older cyclodestructive techniques that fire laser energy through the white of the eye without seeing the target, ECP uses a tiny camera inserted into the eye so the surgeon can see and treat the ciliary processes directly. That visual control makes it gentler on surrounding tissue and has pushed ECP into a growing role across multiple types of glaucoma, from routine open-angle disease paired with cataract surgery to the most stubborn refractory cases.

How ECP Lowers Eye Pressure

All glaucoma treatments ultimately try to bring intraocular pressure (IOP) down to a range that stops ongoing damage to the optic nerve. Most surgical options do this by creating new drainage pathways for the fluid inside the eye. ECP takes a fundamentally different approach: instead of improving outflow, it reduces the amount of fluid the eye produces in the first place. The laser energy is applied to the ciliary processes, which are finger-like projections behind the iris responsible for secreting aqueous humor. When the laser hits these processes, it shrinks them and disrupts the pigmented layer of cells that drives fluid production.¹ The result is less fluid entering the eye, and therefore lower pressure.

Histological studies on cadaveric eyes give a clear picture of why ECP causes less collateral damage than its main alternative, transscleral cyclophotocoagulation (TCP). Under the microscope, ECP causes contraction of the ciliary processes and disruption of the pigmented epithelium while leaving the underlying stromal architecture largely intact. TCP, by contrast, tears through the ciliary body muscle, the stroma, the ciliary processes, and both layers of the ciliary epithelium.² In practical terms, ECP dials down the factory; TCP demolishes it. That difference in tissue damage is why ECP has a better safety reputation and why surgeons are more comfortable using it at earlier stages of glaucoma.

Combining ECP with Cataract Surgery

The most common way ECP is performed today is at the same time as cataract surgery (phacoemulsification). The surgeon is already inside the eye to remove the cloudy lens, so adding ECP treatment to the ciliary processes requires only a few extra minutes and uses the same small incision. This combined procedure has become a workhorse for mild-to-moderate open-angle glaucoma, and the evidence supporting it is now substantial.

A systematic review and meta-analysis comparing phaco-ECP with cataract surgery alone found that adding ECP produced a meaningful additional drop in IOP and reduced the number of glaucoma eye drops patients needed afterward. Cataract surgery alone did yield slightly better visual acuity, but phaco-ECP came out ahead on the metrics that matter for glaucoma control.³ A three-year study tracking patients with open-angle glaucoma who had never had glaucoma surgery found that phaco-ECP reduced IOP by about a fifth to a quarter over the follow-up period, with pressure dropping from roughly 18 mmHg before surgery to about 14 mmHg at three years. The number of glaucoma medications patients needed dropped by more than one agent on average at the one-year mark and remained significantly lower through year three.⁴

That medication reduction deserves emphasis. Glaucoma eye drops are a daily burden, they sting, they can irritate the eye surface over years, and many patients simply forget or stop using them. Any surgery that gets someone off even one daily medication changes their quality of life. Research on patients who underwent minimally invasive glaucoma surgery found that they used fewer drops on average afterward, and they reported statistically improved scores on measures of both glaucoma-specific quality of life and ocular surface comfort.⁵

ECP for Difficult, Refractory Cases

Where ECP really earns its keep is in eyes that have stopped responding to other treatments. Refractory glaucoma, meaning pressure remains dangerously high despite medications and previous surgeries, has historically been treated with transscleral cyclophotocoagulation or tube-shunt implants. ECP offers another option, and in certain situations a less destructive one.

A five-year follow-up study at a tertiary eye center tracked patients with refractory glaucoma who underwent ECP from a posterior (pars plana) approach. Preoperative pressures averaged over 33 mmHg. After surgery, IOP dropped by about 38%, settling near 20 mmHg. The overall success rate after one or more ECP sessions was roughly 65%.⁶ Those are meaningful numbers in a population where “success” can be elusive.

An even more aggressive version of the procedure, sometimes called ECP-plus, extends the laser treatment from the ciliary processes into the pars plana, the flat zone just behind them. In one study, ECP-plus achieved a pressure reduction of about 52% from baseline at the last follow-up visit, compared with 24% for standard anterior ECP. The two-year success rate for ECP-plus was 80%, versus roughly a third for the anterior approach. Complication rates between the two were comparable.⁷ Another study of ECP-plus in refractory eyes showed IOP reductions of over 60% that held steady at 18 to 24 months.⁸ The pars plana approach requires a vitrectomy setup and more surgical experience, but for eyes running out of options, those results are hard to ignore.

How ECP Stacks Up Against Transscleral Cyclophotocoagulation

The most natural comparison for ECP is transscleral cyclophotocoagulation (TCP or TSCP), since both aim to reduce fluid production by treating the ciliary body. The key difference is visibility. TCP fires laser energy through the sclera, essentially shooting blind. The surgeon estimates where the ciliary processes sit, and the laser burns through several tissue layers to reach them. ECP, with its endoscope inside the eye, treats each ciliary process under direct visualization, which allows more precise dosing and avoids unnecessary damage to adjacent structures.

Head-to-head data show roughly equivalent pressure-lowering power. A study in pediatric glaucoma found IOP reductions of about 29% with TCP and 33% with ECP, a difference that was not statistically significant. Success rates were also similar, around 68% for TCP and 62% for ECP.⁹ When both procedures were combined with cataract surgery in adults, complication rates did not differ significantly between the groups.¹⁰

So if outcomes are similar, why choose ECP? In practice, the answer often comes down to context. ECP integrates seamlessly with cataract surgery through an existing incision, making it a natural add-on. TCP, which is applied from outside the eye, does not combine as easily. TCP also tends to be reserved for more advanced or end-stage disease because of its historically higher risk of complications like chronic low pressure or eye shrinkage. The histological evidence showing that ECP preserves the deeper tissue layers while TCP disrupts them helps explain why many surgeons view ECP as the gentler option for eyes that still have useful vision to protect.

ECP Versus Trabeculectomy

Trabeculectomy has been the gold-standard glaucoma surgery for decades. It creates a new drainage channel under a flap in the sclera, essentially building a controlled leak for fluid to escape the eye. It works well, but it demands meticulous postoperative management and carries a nontrivial complication profile, including bleb-related infections, overfiltration leading to dangerously low pressure, and scarring that can cause the surgery to fail.

When both are combined with cataract surgery, the comparison gets interesting. A meta-analysis found that phaco-trabeculectomy produced a bigger pressure drop on the first day after surgery, but by one month and six months the two groups showed no significant difference in IOP. Medication requirements and the need for a second surgery were also comparable. The key divergence was complications: the phaco-ECP group had a significantly lower overall complication rate.¹¹ A single-center study comparing the two found similar IOP levels at six months, though trabeculectomy achieved complete success (no medications needed) more often, while ECP patients more frequently reached the “qualified success” threshold of adequate pressure on some medications.¹²

A broader systematic review covering over 5,000 eyes found a mean success rate of about 74% for ECP procedures compared with roughly 46% for non-ECP alternatives.¹³ That gap is striking, though it comes with caveats: the studies pooled were heterogeneous, and the definition of “success” varied across them. The overall picture is that ECP trades a slightly smaller initial pressure drop for a gentler recovery and fewer serious complications, which makes it especially attractive for patients whose glaucoma is moderate rather than severe.

Pairing ECP with Micro-Invasive Stent Devices

A newer question is whether ECP and micro-invasive glaucoma surgery (MIGS) stent devices like the iStent are better used as alternatives or as partners. The iStent works on the outflow side, creating a tiny bypass through the trabecular meshwork to improve drainage. ECP works on the inflow side, reducing fluid production. In theory, combining both would attack IOP from two directions at once.

The data suggest the theory holds up. A comparison of phaco-ECP, phaco-iStent, or phaco combined with both found that all three approaches lowered IOP and reduced medication dependence at two years.¹⁴ When ECP was compared head-to-head with iStent as add-ons to cataract surgery, phaco-iStent achieved slightly lower IOP levels, though both groups saw significant medication reductions.¹⁵ A multicenter prospective study in Brazil found that adding iStent inject to phaco-ECP produced steeper IOP and medication reductions than phaco-ECP alone, with IOP dropping by about 44% in the combined group versus 24% in the ECP-only group at one year.¹⁶

The practical implication is that for patients who need more IOP reduction than either procedure alone provides, surgeons now have the option of combining inflow reduction with outflow enhancement in a single sitting. Not every patient needs both, but for those with higher baseline pressures or more advanced disease, the combination gives an additional lever to pull.

ECP in Angle-Closure Glaucoma

Most ECP research focuses on open-angle glaucoma, but a growing body of evidence supports its use in angle-closure disease as well. In angle-closure glaucoma, the drainage angle of the eye is physically blocked or narrowed, often by the iris being pushed or pulled forward. Cataract surgery alone helps by removing a thick lens that crowds the front of the eye, but for patients whose pressure remains elevated, ECP can add a further reduction.

A randomized controlled trial comparing phaco-ECP with phaco alone in primary angle-closure glaucoma found that the combined group achieved lower IOP at two years, about 14 mmHg versus nearly 16 mmHg. The combined group also needed significantly fewer medications. Nearly half the phaco-ECP patients achieved a stringent target of 12 mmHg or below, compared with about 14% in the phaco-alone group.¹⁷ An earlier pilot trial showed a similar trend: phaco-ECP produced lower pressures at most follow-up visits, though the difference was only statistically significant at certain time points. Complication rates were comparable between groups.¹⁸

These findings matter because angle-closure patients often need cataract surgery anyway, and the marginal benefit of adding ECP is achieved without extra incisions or a separate operating session. For a disease type where managing pressure often requires multiple interventions, that efficiency is clinically useful.

Using ECP in Children

Pediatric glaucoma is rare, but when it occurs it can be devastating. The available surgeries, angle surgery, tube shunts, trabeculectomy, all carry significant risks in small, growing eyes. ECP offers a less invasive alternative, though the results in children are more modest than in adults.

The largest single-center pediatric cohort study found that a single ECP session had a success rate of about 64% at one year, but that figure dropped to around 36% at three years and only 16% at five years. Cumulative success, allowing for repeat treatments, was about 34% at five years. The one factor strongly associated with success was lower preoperative IOP: children whose pressures started below 32 mmHg fared considerably better.¹⁹ Longer-term data in children who had ECP combined with cataract surgery showed that IOP could be reduced by about 45% over an average follow-up of more than seven years, bringing pressures from the mid-30s down to the high teens on average.²⁰

The takeaway for pediatric glaucoma is that ECP works, but not permanently in most cases. Children tend to need repeat treatments, and many will eventually require additional surgical procedures. Even so, ECP can buy time and keep pressures manageable during the years when the eye is still developing, which has real value. And in rare congenital conditions where standard glaucoma surgeries are difficult or impossible, ECP has been used successfully as a first-line approach.²¹

Who Benefits Most from ECP

Not every glaucoma patient is an ideal candidate. The evidence consistently points to baseline IOP as the single strongest predictor of how much benefit ECP will deliver. A study examining combined phaco-ECP found that patient demographics like age and sex were not associated with surgical success, but higher preoperative IOP was. Patients starting with higher pressures simply had more room for a meaningful drop.²² The pediatric data show the same pattern from the opposite direction: children whose pressures were already below 32 mmHg before surgery had better outcomes.²³

This creates a natural clinical niche. For someone with mild glaucoma and pressures only slightly above normal, phaco-ECP may bring a modest drop that does not eliminate the need for drops entirely. For someone with moderate-to-high pressures and a cataract that needs surgery anyway, the added benefit of ECP becomes much more substantial. And for refractory cases where pressures are in the 30s or higher, especially with the ECP-plus approach, the procedure can deliver dramatic reductions that change the trajectory of the disease.

ECP Beyond Open-Angle Disease

One application that falls outside the usual discussion is the use of ECP in malignant glaucoma, a rare and dangerous condition where aqueous humor gets trapped behind the lens or implant, pushing everything forward and closing the drainage angle. Standard treatments include medications, needle aspiration of the trapped fluid, or vitrectomy. A recent study showed that ECP combined with cataract surgery was effective in resolving malignant glaucoma that developed after trabeculectomy. The laser treatment shrank the ciliary processes enough to widen the gap between them and the lens, relieving the block that caused the misdirection of fluid in the first place.²⁴ This is a niche use case, but it illustrates how the direct visualization afforded by the endoscope allows surgeons to apply the laser in situations where blind external treatment would be far riskier.

ECP’s flexibility is, in many ways, its defining feature. It can be added to cataract surgery for a modest pressure boost, extended into the pars plana for aggressive cases, combined with stent devices for a dual-mechanism approach, and deployed in anatomically challenging eyes where other procedures are impractical. The equipment is specialized and the learning curve is real, which is why ECP is more commonly performed at centers with fellowship-trained glaucoma surgeons. But for patients and referring doctors weighing surgical options, it occupies an increasingly broad middle ground between medical therapy alone and the higher-risk traditional filtering surgeries.